Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPOX versus SOX adjuvant chemotherapy after laparoscopic D2 gastrectomy for advanced gastric cancer
ChiCTR-IPR-17013680Phase 4Not yet recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Apr 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of oxaliplatin, capecitabine and tegafur in gastric cancer (GC) (2 arms), sponsored by Tianjin Medical University General Hospital. Primary endpoints: 3-year overall survival and 3-year progression-free survival. Planned start Apr 2018; status: not yet recruiting.
02
Drugs
oxaliplatincapecitabinetegafur
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR-IPR-17013680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17013680.